ISSN: 2157-7609
+44-77-2385-9429
Essam J Alyamani, Mohamed A Khiyami, Rayan Y Booq, Basel M Alnafjan, Musaad A Altammami and Fayez S Bahwerth
King Abdulaziz City for Science and Technology, KSA
Posters & Accepted Abstracts: J Drug Metab Toxicol
Acinetobacter baumannii is a common opportunistic pathogen that causes major nosocomial infections in hospitals. In this study, we hypothesized a high prevalence of A. baumannii ESBL (Extended Spectrum Betalactamase) among all collected isolates. A. baumannii isolates (n=107) from ICU (Intensive Care Unit) of local hospitals in Makkah were phenotypically and genotypically characterized. The identity and antibiotic susceptibility of A. baumannii strains were determined using the Vitek-2 system. The identified ESBL producers were further analyzed by PCR and sequencing followed by MLST typing. blaTEM, blaSHV and the blaCTX-M group genes 1, 2, 8, 9 and 25 were investigated. Furthermore, blaOXA51 like and blaOXA23 like genes were also examined in the carbapenem resistant A. baumannii isolates. Our data indicated a high prevalence of A. baumannii ESBL producers among the collected strains. Of the 107 A. baumannii isolates, 94% were found to be resistant to cefepime and ceftazidime and aztreonam using the Vitek 2 system. The genes detected encoded TEM, OXA-51 like and OXA-23 like enzymes and CTX-M group proteins 1, 2, 8, 9 and 25. MLST typing identified eight sequence type (ST) groups. The most dominant STs were ST195 and ST557 and all of them belong to worldwide clonal complex (CC) 2. This study has shown that there is a high prevalence of antimicrobial resistance in A. baumannii. The diversity of STs may suggest that new ESBL strains are constantly emerging. The molecular diversity of the ESBL genes in A. baumannii may have contributed to the increased antimicrobial resistance among all isolates.
Essam J Alyamani has completed his PhD from Northeastern University in Boston, USA and Postdoctoral studies from Ottowa University, Canada and Northeastern University, Chicago USA. He is the Director of Microbial Biotechnology at the National Center for Biotechnology, KACST. He has published more than 20 papers in reputed journals and has been serving as a Grant and journals Reviewer since 2008.
Email: eyamani@kacst.edu.sa